ARUNA BIOMEDICAL OFFERS EBRYONIC STEM CELL DERIVED NEURAL CELLS.

ArunA Biomedical, Inc., Athens, Ga., will make its hN2(TM) cells commercially available to the research community in early 2009. The cells, derived from NIH registered human embryonic cell lines, are offered as a normal, consistent population of neural cells in an adherent monolayer format, a product never before offered to the research community. hN2 cells provide a human cell based format for research ranging from Alzheimer's to spinal cord injury and depression.

"ArunA has further developed its adherent monolayer technology by creating hN2(TM), a normal human neural cell ideal for drug screening, toxicology studies and basic neural research and we are pleased to be able to offer these cells commercially to the research market," said David Ray, ArunA's Chief Executive Officer. "By offering our products through multi-national distribution partners, we will provide broad access to the unique tools that may accelerate the pace of neural research with more physiologically relevant cellular research models," Ray said.

About ArunA Biomedical

Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human embryonic stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases. The company's first product, hNP1(TM) (ENSTem-A(TM)), is based on patented technology licensed from the University of Georgia.

For more information, visit http://www.arunabiomedical.com or call 706/542-9191.

Print Get the Mag Weekly Updates